Literature DB >> 25079018

Alect2 amyloidosis: primum non nocere (first, do no harm).

Maria M Picken1.   

Abstract

Said et al. and Larsen et al. present the clinical, morphologic, and genetic features of a recently described amyloidosis, derived from leukocyte chemotactic factor 2 (Alect2), which is beginning to be recognized as an important cause of end-stage renal disease in Hispanics. While the etiology of Alect2 is unknown, and there is currently no effective treatment, it is important to avoid misdiagnosing it as the more common AL, and applying harmful treatment in consequence.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25079018     DOI: 10.1038/ki.2014.45

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  4 in total

Review 1.  Leukocyte Cell-Derived Chemotaxin 2-Associated Amyloidosis: A Recently Recognized Disease with Distinct Clinicopathologic Characteristics.

Authors:  Samih H Nasr; Ahmet Dogan; Christopher P Larsen
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-14       Impact factor: 8.237

2.  Leukocyte Derived Chemotaxin 2 (ALECT2) Amyloidosis.

Authors:  Uday Kulkarni; Anna Valson; Anila Korula; Vikram Mathews
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-07-01       Impact factor: 2.576

3.  Leukocyte chemotactic factor 2-related amyloidosis presenting with severe jaundice and hepatic encephalopathy.

Authors:  Hussam Almasri; Almurtada Razok; Ahmed Badi; Muneera Almohannadi; Abdo Lutf; Mahir Petkar; Abdelnaser Elzouki
Journal:  Clin Case Rep       Date:  2021-12-05

Review 4.  Proteomics and mass spectrometry in the diagnosis of renal amyloidosis.

Authors:  Maria M Picken
Journal:  Clin Kidney J       Date:  2015-09-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.